ArticleInternational journal of nanomedicine2018
A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Non-viral gene delivery systems for osteoarthritis therapy.Biomaterials translational · 2026Review
- The Role of Collagen Genetic Variability in Degenerative Disc Disease and Related Conditions.Current genomics · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Synergism with Shikimic Acid Restores β-Lactam Antibiotic Activity against Methicillin-ResistantMolecules (Basel, Switzerland) · 2024Article
- Engineering approaches for RNA-based and cell-based osteoarthritis therapies.Nature reviews. Rheumatology · 2024Review
- Implications of siRNA Therapy in Bone Health: Silencing Communicates.Biomedicines · 2024Review
- Nanomaterial-assisted theranosis of bone diseases.Bioactive materials · 2023Review
- Recent developments in nanomaterials for upgrading treatment of orthopedics diseases.Frontiers in bioengineering and biotechnology · 2023Review
- Intra-articular drug delivery systems for osteoarthritis therapy: shifting from sustained release to enhancing penetration into cartilage.Drug delivery · 2022Review
- Thermo-Responsive Gel Containing Hydroxytyrosol-Chitosan Nanoparticles (Hyt@tgel) Counteracts the Increase of Osteoarthritis Biomarkers in Human Chondrocytes.Antioxidants (Basel, Switzerland) · 2022Article
- Management of osteoarthritis: From drug molecules to nano/micromedicines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- The advances in nanomedicine for bone and cartilage repair.Journal of nanobiotechnology · 2022Review
- Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs.Trends in pharmacological sciences · 2022Review
- Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.International journal of molecular sciences · 2022Review
- Targeted treatment for osteoarthritis: drugs and delivery system.Drug delivery · 2021Review
- Immunoengineering the next generation of arthritis therapies.Acta biomaterialia · 2021Review
- Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems.Advanced therapeutics · 2021Article
- Short interfering RNA (siRNA)-Based Therapeutics for Cartilage Diseases.Regenerative engineering and translational medicine · 2020Article
- Applications of RNA interference in the treatment of arthritis.Translational research : the journal of laboratory and clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundCartilage degeneration affects millions of people but preventing its degeneration is a big challenge. Although RNA interference (RNAi) has been used in human trials via silencing specific genes, the cartilage RNAi has not been possible to date because the cartilage is an avascular and very dense tissue with very low permeability. PURPOSE: The objective of this study was to develop and validate a novel lipid nanoparticle (LNP)-siRNA delivery system that can prevent cartilage degeneration by knocking down specific genes.
methodsLNP transfection efficiency was evaluated in vitro and ex vivo. Indian Hedgehog (
resultsIn vitro, 100% of chondrocytes were transfected with siRNA in the LNP-siRNA group. In accordance with the cell culture results, red positive signals could be detected even in the deep layer of cartilage tissue cultures treated by LNP-beacon. In vivo data showed that LNP is specific for cartilage, since positive signals were detected by fluorescence molecular tomography and confocal microscopy in joint cartilage injected with LNP-beacon, but not on the surface of the synovium. In the rat model of OA, intraarticular injection of LNP-Ihh siRNA attenuated OA progression, and PCR results showed LNP-Ihh siRNA exerted a positive impact on anabolic metabolism and negative impact on catabolic metabolism.
conclusionThis study demonstrates that our LNP-RNAi delivery system has a significantly chondroprotective effect that attenuates cartilage degeneration and holds great promise as a powerful tool for treatment of cartilage diseases by knocking down specific genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.